SARCOMA FOUNDATION OF AMERICA

AN ENDURING LEGACY

AR22



DEAR FRIENDS

I want to share a heartfelt thank you for all that you do to make a difference in the lives of those touched by sarcoma. I don't know if Mark, Tricia, and Jack had entirely envisioned where SFA would be today. What they did know is that the sarcoma landscape needed change, and that is certainly what SFA has done. Twenty-two years since our founding, I'm proud to say that SFA is the leading private funder of research in the sarcoma community, the principal organization representing sarcoma patients' voice on Capitol Hill, and the most comprehensive patient advocacy organization representing all sarcoma patients.

Thanks to our many and dedicated supporters, in 2022, SFA funded 19 new research grants through our renowned grant program. These projects cover a wide range of research areas and subtypes, including rare subtypes that desperately need more support. This is an increase of $200,000 from last year totaling almost $1 million given through this program in 2022. We also funded research in seven countries: United States, United Kingdom, Italy, Canada, Switzerland, Germany, Netherlands. We committed funding for two SPORE grants with partner institutions, and launched a new grant mechanism, The Last Mile, available for sarcoma researchers to provide funding to strengthen the resubmission of a National Cancer Institute (NCI) NCI R01 proposal thereby leveraging larger government funding. Plus, we have established a fund to assist patients participating in clinical trials by covering expenses related to their participation and have funded our first patients.

We have built a strong and connected sarcoma community through our Race to Cure Sarcoma series through which we have raised millions for sarcoma research. We use some of these funds to directly support sarcoma centers across the country. Our work to provide education and advocacy opportunities have brought together hundreds of people in the sarcoma community to give them information to better understand sarcoma, treatment options, clinical trials and tools to advocate for themselves and for the greater good of the community.

In 2021, and again in 2022, because of SFA's work, the Senate unanimously passed a resolution designating July Sarcoma Awareness Month. We also visited Capitol Hill as part of the Alliance for Childhood Cancer and met with representatives from the House and Senate to ask for their support to allow the Childhood Cancer STAR Act to continue for an additional five years and to ask representatives to cosponsor the Accelerating Kids' Access to Care Act. All truly exciting stuff. I am honored to lead this organization.

Three months after I started at SFA, the world was devastated by the COVID-19 pandemic. And I was wondering how I was going to lead this, a new organization to me, through one of the worst times in recent history. But SFA's supporters did not waiver during this turbulent time. From the people who have joined us to raise significant money for our Race to Cure Sarcoma events across the country, to patients who reach out for information, join us for sarcoma awareness month to raise the profile of the disease, to patients seeking information and participating on our education sessions, along with community oncologists, academia and industry.

All of you represent SFA's dedicated group of supporters. And for that, we are both fortunate and thankful. We often hear stories about lack of diagnosis, no treatment options, lack of advancements, lack of awareness. But we also hear stories of perseverance, courage, and putting greater advancements for sarcoma patients above everything. SFA has and will continue to accomplish many things and we never forget on whose behalf we work.

Thank you for joining us. We could not do this without you.

Sincerely,

Brandi Felser

BRANDI FELSER
Chief Executive Officer

Sarcoma SFA
Foundation of America
finding the cure in our time

THE MISSION OF THE SARCOMA FOUNDATION OF AMERICA (SFA) IS TO ADVOCATE FOR SARCOMA PATIENTS BY FUNDING RESEARCH AND BY INCREASING AWARENESS ABOUT THE DISEASE. THE ORGANIZATION RAISES MONEY TO PRIVATELY FUND GRANTS FOR SARCOMA RESEARCHERS AND CONDUCTS EDUCATION AND ADVOCACY EFFORTS ON BEHALF OF SARCOMA PATIENTS.

RESEARCH

SARCOMA RESEARCH GRANT PROGRAM

SFA's footprint in the sarcoma research landscape continues to grow. Funding of national and international sarcoma research reached new heights in 2022, with the awarding of 19 grants. In addition, a record number of international grants were awarded to researchers based in the United Kingdom, Switzerland, Italy, the Netherlands, Germany, and Finland.

TECHNOBLADE AND LAST MILE RESEARCH AWARDS ESTABLISHED

The untimely death from sarcoma of an internationally known YouTube influencer led to the establishment of the Technoblade Memorial Research Award. Fans of the Minecraft gamer made donations and held fundraising events that brought in significant dollars to fund this award. Dr. Pradeep Shrestha, PhD, of the University of Texas MD Anderson Cancer Center, received the first $50,000 grant for his research into osteosarcoma-lung metastasis. SFA continues to receive donations in memory of Technoblade with many fans conducting Minecraft tournaments and other gaming activities as part of their fundraising efforts.

To support translational research on the etiology, molecular biology, patogenisis, diagnosis and treatment of human sarcomas, SFA launched the Last Mile Research Award. The one-year grant of $150,000 is available to strengthen the resubmission of a National Care institute (NCI) NCI R01 proposal to leverage larger government funding. It covers equipment, supplies and other expenses to support research within the period of performance.

SARCOMA RESEARCH CENTER SUPPORT

SFA is committed to supporting sarcoma care centers and their sarcoma research. In 2022, we funded over $100,000 to sarcoma care centers. Funds from the past year's Race to Cure Sarcoma series helped make this support possible.

EDUCATION, ENGAGEMENT & ADVOCACY

EDUCATION

SFA is committed to providing timely and insightful webinars throughout the year to enable patients to own their diagnosis and make the most educated decisions about their treatments. In 2022, the SFA Education Series hosted three webinars: “Genomics in Sarcoma,” “Immunotherapy Advances in Sarcoma,” and “Promising Research in Sarcoma.” Webinar presenters are leaders in the field with their finger on the pulse of the treatment and research communities. An average of 400 people registered for these webinars and thousands more watched the recording on SFA’s website.

ENGAGEMENT

Regular interaction with thought leaders in the sarcoma arena, including researchers, physicians, and the pharmaceutical industry, provides SFA with a wealth of information and resources. Establishing and maintaining these relationships does much to mold and propel the association’s activities. During the fiscal year, SFA staff attended or exhibited at educational and networking conferences including the American Society of Clinical Oncologists (ASCO), the ASCO Quality Care Symposium, the American Association for Clinical Research Special Sarcoma Meeting, and the Connective Tissue Oncology Society.

ADVOCACY

SFA remained active in the advocacy arena with its support of cancer-related legislation and visits to Capitol Hill. In September, SFA visited Capitol Hill along with the Alliance for Childhood Cancer to meet with representatives from the House and Senate to ask for their support to allow the Childhood Cancer STAR Act to continue for an additional five years. The STAR Act expands opportunities for childhood cancer research, improves efforts to identify and track childhood cancer incidences, and enhances the quality of life for childhood cancer survivors. Representatives were also asked to cosponsor the Accelerating Kids’ Access to Care Act which reduces regulatory burdens to allow children with complex medical needs greater access to out-of-state providers who can best meet their needs.

Throughout the year, SFA joined with other organizations including NORD and the Haystack Project to support legislation to expand rare disease and cancer treatment options.

To assist sarcoma patients participating in clinical trials, SFA launched Jordan’s Dream Fund which covers out-of-pocket expenses associated with participating in these vital research efforts. The fund is named in memory of Jordan Singer who passed away from epithelioid sarcoma in 2017. The fund helps put participation in clinical trials within reach for more patients who would otherwise would not be able to pay for travel, food, and hotel stays.

In December, SFA announced that John Franklin-Myers of the New York Jets would serve as its official ambassador. Franklin-Myers’ past support of SFA includes his participation in the National Football League’s My Cause, My Cleats program. For this fundraiser, he had a pair of custom cleats designed to reflect his support of SFA and auctioned them to benefit the foundation. In addition, he formed a team to participate in the 2022 New Jersey Race for the Cure. Both activities successfully built awareness of SFA’s mission and assisted with raising funds for sarcoma research grants.



EVENTS

RACE TO CURE SARCOMA

Beginning in March, SFA supporters were literally off to the races with the Race to Cure Sarcoma series which kicked off in April in Atlanta, Ga., and was held in 18 cities across the country. Over 5,200 participants helped raise over $1.1 million as well as awareness about sarcoma and the need for research for this often-overlooked disease.

STAND UP TO SARCOMA GALA

The Stand Up to Sarcoma Gala held at the Edison in New York City in September delighted attendees with its entertainment, auction and recognition program. But more importantly, the standing-room-only event raised over $540,000. The Amira Yunis Courage Award was presented to sarcoma survivor Todd Barron of West Palm Beach, Fla. Crystall L. Mackall, MD, of Stanford University received the Nobility in Science Award. The Compassionate Care Award was given to Johns Hopkins' Devon Ciampa, LCSW, OSW-C. Representatives from Adaptimmune Therapeutics accepted the Vision of Hope Award.

PATIENTS AND FAMILIES SUPPORTING SARCOMA RESEARCH

The commitment of sarcoma patients, survivors and family members to raise dollars for a cure cannot be overstated. Throughout the year, these caring individuals helped keep SFA in the public eye and did so in many novel and creative ways. Haunted houses, auto racing, online gaming, lemonade stands, and boxing are just a few of the activities our supporters conducted as fundraisers to benefit SFA.

OUTREACH FOR AWARENESS

The year was marked by an exceptional series of outreach and awareness activities, the most significant of which was Sarcoma Awareness Month in July. The recognition month was marked by a social media campaign, development of customized graphics including those for Wear Yellow Day on July 12 and an email campaign.

Throughout the year, SFA expressed its solidarity with all cancer patients by acknowledging National Childhood Cancer Awareness Month and other cancer recognition days and months through social media posts, website graphics, and other communications.

Other sarcoma awareness activities of note include the growth of SFA's social media presence. This presence included the posting of city-specific ads promoting the Race to Cure Sarcoma series and an overall increase in the number of posts across all platforms.

Another step toward enhancing SFA's profile was its inaugural participation in the Marine Corps Marathon in October. The SFA team of four included Dean Frohlich, PhD, the Foundation's Director of Scientific Affairs, Stephanie Knappe (participating in 10K), Brian Rodriguez and Leticia Rousseve. The Marathon Team raised money for research, advocacy and awareness.

FINANCIALS



Information from Sarcoma Foundation of America, Inc. independent audit for year ended December 31, 2022

Your Support

FUNCTIONAL EXPENSES

PROGRAM	$	2,162,071	*(75.6%)*
MGMT AND GENERAL		356,641	*(12.4%)*
FUNDRAISING		339,851	*(11.8%)*
TOTAL	$	**2,858,563**	



ASSETS

Current assets		
Cash and cash equivalents	$	2,471,740
Contributions receivable		164,128
Other receivable, current		6,000
Prepaid Expenses		45,521
TOTAL CURRENT ASSETS	**$**	**2,687,389**
Property and equipment		
Leasehold improvements	$	78,190
Machinery and equipment		49,919
Furniture		13,443
Website		39,000
Total property and equipment		180,552
Accumulated depreciation and amortization		(119,283)
NET PROPERTY AND EQUIPMENT	**$**	**61,269**
Investments	$	6,782,147
Other assets		
Right-of-use asset, net		222,510
Donated jewelry		10,000
Other receivables, noncurrent		38,871
Deposits		3,416
Total other assets		274,797
TOTAL ASSETS	**$**	**9,805,602**



LIABILITIES

Current liabilities		
Grants payable	$	106,449
Accounts Payable		34,033
Accrued Expenses		129,321
Operating lease liability, current portion		78,575
TOTAL CURRENT LIABILITIES	**$**	**348,378**
Long term liabilities		
Operating lease liability, net of current portion	$	190,798
TOTAL LIABILITIES	**$**	**539,176**

NET ASSETS

Without donor restrictions		
Designated by the board	$	883,578
Designated by the board for endowment		620,555
Total designated by the board		1,504,133
Undesignated		5,865,678
Total without donor restrictions		7,369,811
With donor restrictions		1,896,615
TOTAL NET ASSETS	**$**	**9,266,426**
TOTAL LIABILITIES AND NET ASSETS	**$**	**9,805,602**

	WITHOUT DONOR RESTRICTIONS	WITH DONOR RESTRICTIONS	TOTAL
REVENUES			
Grants and contributions of cash and other financial assets	$ 2,182,535	$ 135,000	$ 2,317,535
Contributions of non-financial assets	53,996		53,996
Special events	1,589,109		1,589,109
Costs of direct benefits to donors	(261,450)		(261,450)
Investment loss, net	(858,692)	(38,818)	(897,510)
Other revenue	641		641
Net assets released from restrictions	321,040	(321,040)	
TOTAL REVENUE	**3,027,179**	**(224,858)**	**2,802,321**
EXPENSES			
Program services	2,162,071		2,162,071
Management and general	356,641		356,641
Fundraising	339,851		339,851
TOTAL EXPENSES	**2,858,563**		**2,858,563**
CHANGE IN NET ASSETS	**168,616**	**(224,858)**	**(56,242)**
Net assets, beginning of year	7,201,195	2,121,473	9,322,668
NET ASSETS, END OF YEAR	**$ 7,369,811**	**$ 1,896,615**	**$ 9,266,426**

Sarcoma SFA
Foundation of America
finding the cure in our time

9899 Main Street
Suite 204
Damascus, MD 20872

curesarcoma.org